ADG116
Advanced/Metastatic Solid Tumors
Phase 1Active
Key Facts
About Adagene
Adagene's mission is to transform antibody drug discovery and development through its proprietary AI-powered Dynamic Precision Library (DPL) platform. The company has achieved significant validation through strategic collaborations with global pharmaceutical partners and has advanced a pipeline of nine candidates, including its lead SAFEbody-masked anti-CTLA-4 program, ADG126, which has shown a compelling clinical safety profile. Its strategy focuses on leveraging computational design to create precision biologics with enhanced therapeutic indices, aiming to deliver first- or best-in-class therapies in oncology while monetizing its platform through partnerships.
View full company profileTherapeutic Areas
Other Advanced/Metastatic Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-1158 (INCB001158) | Calithera Biosciences | Phase 1/2 |
| TAK-676 | Thermo Fisher Scientific | Phase 1/2 |
| ADG126 | Adagene | Phase 1b/2 |